A detailed history of Royal Bank Of Canada transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 36,514 shares of VERV stock, worth $201,922. This represents 0.0% of its overall portfolio holdings.

Number of Shares
36,514
Previous 10,490 248.08%
Holding current value
$201,922
Previous $51,000 245.1%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$4.4 - $7.86 $114,505 - $204,548
26,024 Added 248.08%
36,514 $176,000
Q2 2024

Aug 14, 2024

SELL
$4.76 - $12.79 $34,086 - $91,589
-7,161 Reduced 40.57%
10,490 $51,000
Q1 2024

Nov 05, 2024

BUY
$10.81 - $17.96 $77,410 - $128,611
7,161 Added 68.27%
17,651 $234,000
Q1 2024

May 15, 2024

BUY
$10.81 - $17.96 $45,402 - $75,432
4,200 Added 31.22%
17,651 $234,000
Q4 2023

Feb 14, 2024

SELL
$8.84 - $18.7 $56,832 - $120,222
-6,429 Reduced 32.34%
13,451 $187,000
Q3 2023

Nov 14, 2023

BUY
$11.42 - $20.82 $31,987 - $58,316
2,801 Added 16.4%
19,880 $263,000
Q2 2023

Aug 14, 2023

BUY
$13.34 - $19.9 $78,119 - $116,534
5,856 Added 52.18%
17,079 $320,000
Q1 2023

May 15, 2023

SELL
$14.3 - $24.01 $18,590 - $31,213
-1,300 Reduced 10.38%
11,223 $161,000
Q4 2022

Feb 14, 2023

BUY
$17.85 - $40.7 $93,480 - $213,145
5,237 Added 71.88%
12,523 $242,000
Q3 2022

Nov 14, 2022

BUY
$15.63 - $41.49 $96,202 - $255,370
6,155 Added 544.21%
7,286 $250,000
Q2 2022

Aug 15, 2022

SELL
$11.14 - $23.17 $16,041 - $33,364
-1,440 Reduced 56.01%
1,131 $17,000
Q1 2022

May 16, 2022

SELL
$20.92 - $39.36 $93,198 - $175,348
-4,455 Reduced 63.41%
2,571 $58,000
Q4 2021

Feb 14, 2022

SELL
$31.94 - $54.82 $58,577 - $100,539
-1,834 Reduced 20.7%
7,026 $260,000
Q3 2021

Nov 15, 2021

BUY
$46.0 - $73.99 $80,960 - $130,222
1,760 Added 24.79%
8,860 $416,000
Q2 2021

Aug 16, 2021

BUY
$31.92 - $60.25 $226,632 - $427,775
7,100 New
7,100 $428,000

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $331M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.